<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01100853</url>
  </required_header>
  <id_info>
    <org_study_id>811095</org_study_id>
    <secondary_id>P50DA012756</secondary_id>
    <secondary_id>2009-013647-10</secondary_id>
    <nct_id>NCT01100853</nct_id>
  </id_info>
  <brief_title>Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland</brief_title>
  <official_title>Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Society of Alcoholism and other Addictions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Until positive results were found with oral naltrexone, no medication has been effective
      against amphetamine dependence. The primary aim of this pilot study is to replicate the
      findings of the Swedish team that showed oral Naltrexone prevented relapse to amphetamine
      addiction and to extend their results by randomizing treatment-seeking amphetamine addicted
      patients to a 6 month course of VIVITROL (naltrexone for extended-release injectable
      suspension) or VIVITROL placebo. Patients in each group will receive drug counseling.
      VIVITROL is administered monthly and may be a better test of efficacy than tablets that must
      be taken daily.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number Negative Urines (Proportion Negative Urines)</measure>
    <time_frame>24 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number Negative Urines (Proportion Negative Urines) Amphetamine</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amphetamine Craving Scale</measure>
    <time_frame>24 weeks</time_frame>
    <description>The Amphetamine Craving Scale is a visual analogue scale, which is scored by indicating the level of craving on a 100 mm line, where 0 is no craving at all and 100 is the highest level of craving experienced. Scores are derived from measuring their placement on the line, yielding scores from 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory</measure>
    <time_frame>24 weeks</time_frame>
    <description>The Beck Depression Inventory is a self-administered questionnaire that assess the severity of depressive symtpoms. It consists of 21 items about how the subject has been feeling in the last week, and each item has a set of at least four possible answer choices, ranging in intensity, yielding scores from 0-3, with a total possible score of 63. Higher scores indicate more severe depressive symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk Assessment Battery</measure>
    <time_frame>24 weeks</time_frame>
    <description>The Risk Assessment Battery is a 41 item self-report questionnaire that assess risk behaviors related to HIV infection over the past 6 months. The measure yields a Drug risk score ranging from 0-22 and a Sex risk score ranging from 0-18, with higher scores indicating more risk; these scores are added to yield a Total RAB score ranging from 0-40. This total scores is then divided by 40 to yield a RAB Scale Score from 0-1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prior Admissions to Vogur Hospital</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of prior admissions due to substance dependence. The term &quot;prior admissions&quot; refers to admissions before enrollment, thus Baseline is the appropriate Time Frame.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Amphetamine Dependence</condition>
  <arm_group>
    <arm_group_label>Extended release VIVITROL injection 380 mg, 24 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Efficacy of 24 week course of Extended Release VIVITROL 380 mg with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VIVITROL placebo injection, 24 weeks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIVITROL injection and VIVITROL Placebo Injection , 24 weeks</intervention_name>
    <description>Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)</description>
    <arm_group_label>Extended release VIVITROL injection 380 mg, 24 weeks</arm_group_label>
    <arm_group_label>VIVITROL placebo injection, 24 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 or above;

          2. Diagnosis of amphetamine dependence as defined by DSM-IV-TR with 10 or more days of
             amphetamine use in the past month, and patient and clinician identify amphetamine
             dependence as the main problem;

          3. Abstinent from substances (alcohol, amphetamines, cannabinoid, cocaine, hallucinogens,
             opioids, benzodiazepines [unless used to treat alcohol withdrawal] for at least 7 days
             prior to receiving study drug or placebo;

          4. Provision of telephone numbers/contacts of three or more people that are likely to
             know where can be located if unable to be contacted directly;

          5. Successfully complete 7-10 day assessment and study baseline measures at Vogur

        Exclusion Criteria:

          1. Any liver test &gt;5 times the top limit of normal; Physiologically dependent on opioids
             or other substances (nicotine excepted) at time of admission to Vogur;

          2. Suspected or known concomitant use of opioid analgesics, positive opioid urine drug
             test or positive naloxone challenge:

          3. Schizophrenia, Bipolar I or other non-substance related psychotic disorder; Severely
             depressed, suicidal or homicidal: Dementia: Inability to understand the informed
             consent;

          4. Planning to move from the Reykjavík area or enter jail within the next 12 months;

          5. Likely to receive opioid analgesics in next 6 months associated with possible or
             scheduled surgery or procedure;

          6. Known hypersensitivity to naltrexone, polyactide-co-glycolide (PLG);
             carboxymethylcellulose, or any other component of the diluent;

          7. Female subjects who are pregnant or lactating, or of child bearing potential who are
             not using acceptable methods of birth control;

          8. A body habitus that precludes use of the customized needle for intramuscular
             injection, based on clinical judgment;

          9. Use of an investigational agent in the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Pettinati, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Woody, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SAA National Center of Addiction Medicine, Vogur Hospital</name>
      <address>
        <city>Storhofda 45</city>
        <state>Reykjavík</state>
        <zip>112</zip>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iceland</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2010</study_first_submitted>
  <study_first_submitted_qc>April 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2010</study_first_posted>
  <results_first_submitted>July 9, 2013</results_first_submitted>
  <results_first_submitted_qc>November 25, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2014</results_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>amphetamine dependence</keyword>
  <keyword>amphetamine injection</keyword>
  <keyword>VIVITROL/VIVITROL placebo</keyword>
  <keyword>amphetamine craving</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Amphetamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VIVITROL Injection, 24 Weeks</title>
          <description>Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)</description>
        </group>
        <group group_id="P2">
          <title>VIVITROL Placebo Injection, 24 Weeks</title>
          <description>Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Received &lt;4 study injections</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VIVITROL Injection, 24 Weeks</title>
          <description>Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)</description>
        </group>
        <group group_id="B2">
          <title>VIVITROL Placebo Injection, 24 Weeks</title>
          <description>Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.51" spread="1.11"/>
                    <measurement group_id="B2" value="31.59" spread="1.34"/>
                    <measurement group_id="B3" value="31.55" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Iceland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number Negative Urines (Proportion Negative Urines)</title>
        <time_frame>24 Weeks</time_frame>
        <population>Urine drug screens negative amphetamine</population>
        <group_list>
          <group group_id="O1">
            <title>VIVITROL Injection, 24 Weeks</title>
            <description>Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)</description>
          </group>
          <group group_id="O2">
            <title>VIVITROL Placebo Injection, 24 Weeks</title>
            <description>Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)</description>
          </group>
        </group_list>
        <measure>
          <title>Number Negative Urines (Proportion Negative Urines)</title>
          <population>Urine drug screens negative amphetamine</population>
          <units>Urine Drug Screen</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="560"/>
                    <measurement group_id="O2" value="634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amphetamine Craving Scale</title>
        <description>The Amphetamine Craving Scale is a visual analogue scale, which is scored by indicating the level of craving on a 100 mm line, where 0 is no craving at all and 100 is the highest level of craving experienced. Scores are derived from measuring their placement on the line, yielding scores from 0 to 100.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VIVITROL Injection, 24 Weeks</title>
            <description>Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)</description>
          </group>
          <group group_id="O2">
            <title>VIVITROL Placebo Injection, 24 Weeks</title>
            <description>Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)</description>
          </group>
        </group_list>
        <measure>
          <title>Amphetamine Craving Scale</title>
          <description>The Amphetamine Craving Scale is a visual analogue scale, which is scored by indicating the level of craving on a 100 mm line, where 0 is no craving at all and 100 is the highest level of craving experienced. Scores are derived from measuring their placement on the line, yielding scores from 0 to 100.</description>
          <units>VAS Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" spread="4"/>
                    <measurement group_id="O2" value="46.92" spread="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Depression Inventory</title>
        <description>The Beck Depression Inventory is a self-administered questionnaire that assess the severity of depressive symtpoms. It consists of 21 items about how the subject has been feeling in the last week, and each item has a set of at least four possible answer choices, ranging in intensity, yielding scores from 0-3, with a total possible score of 63. Higher scores indicate more severe depressive symptoms.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VIVITROL Injection, 24 Weeks</title>
            <description>Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)</description>
          </group>
          <group group_id="O2">
            <title>VIVITROL Placebo Injection, 24 Weeks</title>
            <description>Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Depression Inventory</title>
          <description>The Beck Depression Inventory is a self-administered questionnaire that assess the severity of depressive symtpoms. It consists of 21 items about how the subject has been feeling in the last week, and each item has a set of at least four possible answer choices, ranging in intensity, yielding scores from 0-3, with a total possible score of 63. Higher scores indicate more severe depressive symptoms.</description>
          <units>BDI Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.63" spread="1.40"/>
                    <measurement group_id="O2" value="14.08" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk Assessment Battery</title>
        <description>The Risk Assessment Battery is a 41 item self-report questionnaire that assess risk behaviors related to HIV infection over the past 6 months. The measure yields a Drug risk score ranging from 0-22 and a Sex risk score ranging from 0-18, with higher scores indicating more risk; these scores are added to yield a Total RAB score ranging from 0-40. This total scores is then divided by 40 to yield a RAB Scale Score from 0-1.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VIVITROL Injection, 24 Weeks</title>
            <description>Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)</description>
          </group>
          <group group_id="O2">
            <title>VIVITROL Placebo Injection, 24 Weeks</title>
            <description>Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Assessment Battery</title>
          <description>The Risk Assessment Battery is a 41 item self-report questionnaire that assess risk behaviors related to HIV infection over the past 6 months. The measure yields a Drug risk score ranging from 0-22 and a Sex risk score ranging from 0-18, with higher scores indicating more risk; these scores are added to yield a Total RAB score ranging from 0-40. This total scores is then divided by 40 to yield a RAB Scale Score from 0-1.</description>
          <units>Total Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.14" spread=".62"/>
                    <measurement group_id="O2" value="5.98" spread=".43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prior Admissions to Vogur Hospital</title>
        <description>Number of prior admissions due to substance dependence. The term “prior admissions” refers to admissions before enrollment, thus Baseline is the appropriate Time Frame.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VIVITROL Injection, 24 Weeks</title>
            <description>Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)</description>
          </group>
          <group group_id="O2">
            <title>VIVITROL Placebo Injection, 24 Weeks</title>
            <description>Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)</description>
          </group>
        </group_list>
        <measure>
          <title>Prior Admissions to Vogur Hospital</title>
          <description>Number of prior admissions due to substance dependence. The term “prior admissions” refers to admissions before enrollment, thus Baseline is the appropriate Time Frame.</description>
          <units>Number of admissions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.78" spread=".87"/>
                    <measurement group_id="O2" value="4.88" spread=".63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number Negative Urines (Proportion Negative Urines) Amphetamine</title>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VIVITROL Injection, 24 Weeks</title>
            <description>Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)</description>
          </group>
          <group group_id="O2">
            <title>VIVITROL Placebo Injection, 24 Weeks</title>
            <description>Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)</description>
          </group>
        </group_list>
        <measure>
          <title>Number Negative Urines (Proportion Negative Urines) Amphetamine</title>
          <units>Urine Drug Screen</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="560"/>
                    <measurement group_id="O2" value="634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>VIVITROL Injection, 24 Weeks</title>
          <description>Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)</description>
        </group>
        <group group_id="E2">
          <title>VIVITROL Placebo Injection, 24 Weeks</title>
          <description>Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain, elevated liver enzymes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitilization due to relapse to substance disorder</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Potential suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea, diarrhea, discomfort/pain from stomach, heartburn</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E2" events="13" subjects_affected="7" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Other, feeling unwell, fever, loss of appetite, joint pain, pruritus, sore throat, etc.</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT level &gt;5 times normal range</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness, fatigue, fainting sensation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Symptoms of depression and/or anxiety</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Helen Pettinati</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-222-3200 ext 139</phone>
      <email>helenp@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

